A microdose study of 14C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung
To explore, in a microdose (phase-0) study, the pharmacokinetics, bioavailability and concentrations in key compartments of the lung, of AR-709, a novel diaminopyrimidine antibiotic for the treatment of respiratory infection.
Four healthy men each received two single, 100 μg microdoses of 14C-AR-709, 7 days apart: the first was administered intravenously (IV), the second orally. Plasma pharmacokinetics of 14C and unchanged AR-709 were obtained by high-performance liquid chromatography and accelerator mass spectrometry (AMS). Next, 15 healthy men received a single, 100 μg microdose of 14C-AR-709 IV. Plasma, bronchoalveolar lavage fluid, alveolar macrophages and bronchial mucosal biopsy samples were analysed by AMS.
After IV administration, clearance of AR-709 was 496 mL/min, volume of distribution was 1,700 L and the absolute oral bioavailability was 2.5 %. Excretion in urine was negligible. At 8–12 h after IV dosing, 14C concentrations in lung samples were 15- (bronchial mucosa) to 200- (alveolar macrophages) fold higher than in plasma. In alveolar macrophages, 14C was still mostly associated with AR-709 at 12 h after dosing.
The results of this microdose study indicate that AR-709 attains concentrations appreciably higher within the lung than in plasma. Its low oral bioavailability however, precludes oral administration. Although IV administration would appear to be an effective route of administration, this would limit the use of AR-709 to a clinical setting and would therefore be economically unsustainable. If further clinical development were to be undertaken, therefore, an alternative route of administration would be necessary.
KeywordsMicrodose Diaminopyrimidine antibiotic Accelerator mass spectrometry Bronchial alveolar lavage Pharmacokinetics
- 2.Mukhija S, Bandera M, Parisi S, Rigo S, Lieb S, Lociuro S, Gillessen D, Islam K (2006) AR709—an investigational diaminopyrimidine: inhibition, binding and mode of action. In: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Fransisco, Abstr F1-1955Google Scholar
- 6.McKenney D, Murphy T, Little S, Gordon L, Islam K, Lociuro S (2007) Efficacy of AR-709 in pneumococcal murine pneumonia. In: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. ChicagoGoogle Scholar
- 10.Committee for Medicinal Products for Human Use (CPMP)/International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2009) ICH Topic M3 Note for Guidance on non-clinical safety pharmacology studies for human pharmaceuticals. CPMP/ICH/286/95. CPMP/ICH, London/GenevaGoogle Scholar
- 12.The BAL Cooperative Group Steering Committee (1990) Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 141:S166–S202Google Scholar
- 13.Turteltaub KW, Felton JS, Gledhill BL, Vogel JS, Southon JR, Caffee MW, Finkel RC, Nelson DE, Proctor ID, Davis JC (1990) Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. Proc Natl Acad Sci USA 87(14):5288–5292PubMedCrossRefGoogle Scholar
- 15.Committee for Medicinal Products for Human Use (2004) Position paper on non-clinical safety studies to support clinical trials with a single microdose. Position paper CPMP/SWP/2599. European Medicines Agency, LondonGoogle Scholar
- 16.Albert A, Brown DJ (1954) Purine studies part I. Stability to acid and alkali. Solubility, ionization, comparison with pteridines. J Chem Soc 2060–2071Google Scholar
- 20.Klech H, Pohl W (1989) Report of the European Society of Pneumology Task Group on BAL. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J 2(561–585)Google Scholar
- 24.Lappin G, Garner RC (2004) Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry. Anal Biochem 378(2):356–364Google Scholar
- 27.Rowland M, Benet LZ (2011) Clinical trials and translational medicine commentaries. J Pharm Sci 100:4047–4049Google Scholar
- 28.Lappin G, Noveck R, Burt T (2013) Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol 9 (7):in pressGoogle Scholar
- 30.Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Brian Houston J, Oosterhuis B, Bjerrum OJ, Grynkiewicz G, Alder J, Rowland M, Garner C (2011) Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur J Pharm Sci 43:141–150PubMedCrossRefGoogle Scholar